Use access key #2 to skip to page content.
$32.92 -1.76 (-5.07%)
10/6/2008 4:00 PM

Invitrogen Corp (IVGN)

CAPS Rating:
****

A developer, manufacturer and marketer of research tools in reagent, kit and high-throughput applications forms to customers engaged in life sciences research, drug discovery, diagnostics and the commercial manufacture of biological products.

View All Commentary (IVGN)

Recs

1

Avatar Leftarmround (< 20) Submitted: 1/31/07 1:46 PM : Outperform Start Price: $30.47 IVGN Score: 34.73

Future of Rx pharma is genetics, with related R&D efforts expanding exponentially worldwide. IVGN is omnipresent in genetic/biotec supply field and a heavy M&A investor. Despite recent depression from upsets in management, their platform is such that even poor stewardship will have difficulty in maintaining underperformance long-term.

Report this Post Replies: 0 | Reply

Featured Broker Partners